administered.

TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; an Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; and an RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly.

We are supported by a strong network of industry, governmental agencies and academic collaborators and have received over $5.0 million in equity and non-dilutive funding (NIH, IRS grants and programs). Our portfolio of vaccine candidates has a prospective addressable market of over US$5 billion in annual worldwide sales. Our IP is strong and protected by multiple domestic and international patent applications. We are actively pursuing strategic alliances, licensing arrangements and collaborations in order to bring our products closer to the market. We are seeking funding to start human testing of 1 to 3 vaccine candidates.